Gastrointestinal Cancer News

The addition of nivolumab to first-line chemotherapy significantly improved PFS, but not OS, for patients with advanced or recurrent HER2-negative gastric and gastroesophageal junction cancer, according to phase 3 study findings.

Our understanding of pancreatic cancer biology is advancing rapidly.

Opioids are a potent pharmacologic option for managing recurrent pain experienced by cancer survivors.

The FDA granted fast track designation to DKN-01 for the treatment of certain patients with gastric cancer or gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.

The addition of pembrolizumab to chemotherapy improved OS, PFS and objective response rates among patients with untreated, advanced esophageal and esophagogastric junction adenocarcinoma, results of the phase 3 KEYNOTE-590 study showed.

Nivolumab plus chemotherapy increased PFS and OS compared with chemotherapy alone among previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, study results showed.

Drinking coffee may reduce the risk for disease progression and death among patients with advanced or metastatic colorectal cancer, according to results of a prospective observational cohort study published in JAMA Oncology.

The European Society for Medical Oncology announced the recipients of this year’s ESMO Awards.

Henry A. Pitt, MD, has been named chief of oncologic quality at Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital.

First-line pembrolizumab appeared noninferior to chemotherapy and led to fewer adverse events among certain patients with advanced gastric or gastroesophageal junction cancer, according to results of the phase 3 KEYNOTE-062 study.